Attenuated T Cell Responses to a High-Potency Ligand In Vivo by Corse, Emily et al.
Attenuated T Cell Responses to a High-Potency Ligand In
Vivo
Emily Corse
1, Rachel A. Gottschalk
1,2, Michelle Krogsgaard
3, James P. Allison
1*
1Department of Immunology, Howard Hughes Medical Institute and Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center, New York, New
York, United States of America, 2Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, New York, United States
of America, 3Department of Pathology and New York University (NYU) Cancer Institute, NYU School of Medicine, New York, New York, United States of America
Abstract
ab T cell receptor (TCR) recognition of foreign peptides bound to major histocompatibility complex (pMHC) molecules on
the surface of antigen presenting cells is a key event in the initiation of adaptive cellular immunity. In vitro, high-affinity
binding and/or long-lived interactions between TCRs and pMHC correlate with high-potency T cell activation. However, less
is known about the influence of TCR/pMHC interaction parameters on T cell responses in vivo. We studied the influence of
TCR/pMHC binding characteristics on in vivo T cell immunity by tracking CD4
+ T cell activation, effector, and memory
responses to immunization with peptides exhibiting a range of TCR/pMHC half-lives and in vitro T cell activation potencies.
Contrary to predictions from in vitro studies, we found that optimal in vivo T cell responses occur to ligands with
intermediate TCR/pMHC half-lives. The diminished in vivo responses we observed to the ligand exhibiting the longest TCR/
pMHC half-life were associated with attenuation of intracellular signaling, expansion, and function over a broad range of
time points. Our results reveal a level of control over T cell activation in vivo not recapitulated in in vitro assays and highlight
the importance of considering in vivo efficacy of TCR ligands as part of vaccine design.
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Introduction
Activation of T cells by peptides bound to major histocompat-
ibility complex (pMHC) molecules on antigen presenting cells
(APCs) initiates the development of adaptive immunity to
pathogens and is characterized by relatively low affinity but highly
sensitive interactions between TCRs and pMHC [1,2]. Our
understanding of the biochemical requirements for T cell activa-
tion by pMHC ligands has been advanced by the use of peptides
that vary from the natural ligands at TCR contact residues [3,4].
Since the initial report of a kinetic basis for TCR ligand
discrimination [5], the affinity and half-life of TCR/pMHC
interactions have been studied as important determinants of T cell
activation potency. It has been generally accepted that pMHC
ligands with greater affinity/slower off-rates result in a higher
potency of T cell activation [6–9], although there are exceptions
[10]. Insight into apparent discrepancies among studies that found
the affinity [8,9,11] versus the half-life [6,10,12] of the TCR/
pMHC interaction to be the most influential determinant of T cell
activation potency has been provided by a recent report in which
affinity (KD) was found to be the more closely associated with
potency when the association rate (ka) was large (.10
5 M
21s
21),
whereas half-life or dissociation rate (kd) correlated well with
potency when kon was small (10
3 M
21s
21) [13]. In both cases
(small or large ka), the strongest interactions, whether defined by
kinetic or equilibrium parameters, yielded the most potent T cell
responses.
In addition to its influence upon the magnitude of T cell
responses, TCR ligand potency is also thought to influence the
outcome of in vitro CD4
+ helper T cell differentiation [14,15], as
well as T cell motility during early stages of in vivo T cell
activation [16,17]. It is critical to understand how biochemical
parameters of TCR recognition influence the entire course of an in
vivo CD4
+ T cell response, especially given that the goal of many
vaccine strategies is to elicit strong, persistent T cell responses to
pathogens and tumors. The importance of CD4
+ T cell help in
vaccination protocols is underscored by the suboptimal responses
elicited by minimal CD8
+ T cell epitopes in many cases [18].
We examined the effect of TCR ligand potency upon in vivo
CD4+ T cell responses using adoptively transferred 5C.C7 T cells
activated by immunization with lipopolysaccharide (LPS) and
moth cytochrome c (MCC) peptide, or related ligands of varying
potency of in vitro T cell activation [19–23], including one peptide
initially identified as an in vitro superagonist ligand for the
cytochrome c-reactive 2B4 TCR [24]. This strategy resulted in
fully functional differentiation of effector and memory T cells and
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multiple stages of the T cell response, which is not possible using in
vitro methods, in a system with few variables that is relevant to
CD4
+ T cell vaccine design [18]. In contrast to predictions from
the in vitro hierarchy of ligand potency and the commonly held
assumption that more potent T cell responses result from longer-
lived TCR/pMHC interactions during T cell recognition, we
observed an optimal in vivo T cell response in the middle of the
avidity spectrum.
A recent study of CD8
+ T cell responses to Listeria monocytogenes
expressing various OT-1 TCR ligands [25] showed a good
correlation between ligand potency in vitro and the magnitude of
the T cell response in vivo, i.e. the natural OT-1 TCR ligand
SIINFEKL exhibited the most potent responses in vitro and in
vivo. In our study of in vivo CD4
+ T cell responses, we were able
to examine a ligand that is stronger in vitro than the natural
5C.C7 TCR ligand MCC (88–103) [24], and the blunted
responses we observed to this ligand in vivo were associated with
attenuation of signaling, proliferation, and function at several
points during the T cell response, rather than increased cell death,
overactivation, or clonal exhaustion. These results point to an
upper limit of in vivo TCR ligand potency, which could serve to
protect against deleterious inflammatory effects during responses
to strong TCR stimulation, and highlight the importance of
considering the in vivo efficacy of TCR ligands as part of vaccine
strategies that aim to promote high-avidity T cell recognition of
tumors or pathogens [11].
Results
Biochemical Determinants of 5C.C7 TCR Ligand Potency
We used 5C.C7 TCR transgenic T cells, which recognize a
peptide from MCC in the context of the mouse MHC class II
molecule I-E
k [3], to study the effect of peptide/MHC ligand
potency on in vivo CD4
+ T cell activation. Amino acid
substitutions of MCC (88–103) result in a panel of peptide ligands
that bind to I-E
k equally well [24] but exhibit a range of potency
for activation of 5C.C7 T cells in vitro [19–23]. Surface plasmon
resonance (SPR) was used to study the kinetics of the interaction of
purified 5C.C7 TCR with immobilized pMHC complexes
(Figure 1). Figure 1A shows plots of resonance units (RU) after
TCR injection for 102S/I-E
k (14.3 mM TCR), K3/I-E
k (1.8–
14.3 mM TCR), MCC/I-E
k (1.8–14.3 mM TCR), and K5/I-E
k
(1.8–14.3 mM TCR). SPR signal plots of all four pMHC
complexes with 7.1 mM and 14.3 mM injected TCR are shown
in Figure 1B and C, respectively. The observed SPR curves (shown
in Figure 1 as colored symbols) were fitted to a 1:1 Langmuir
binding model (shown in Figure 1 as solid black lines) to calculate
ka and kd constants, which were used to derive half-life and KD of
the TCR/pMHC interactions (Table 1). As shown in Figure 1A,
the on- or off-rates of association of 5C.C7 with 102S/I-E
k were
too fast to be accurately measured by SPR. The data indicate that
Author Summary
As an important part of immune system, T cells fight
infections by recognizing signs of foreign invaders. A
molecule on the surface of these cells—called the T cell
receptor—recognizes and binds to protein components
(peptides) from bacteria, viruses, and other pathogens that
are displayed on the surface of other cells. The T cells can
then use this information to orchestrate the fight against
infection. Vaccination involves injecting into the body
foreign peptides that mimic a pathogen, therefore tricking
it into raising a T cell response against that pathogen that
will be protective in the event of a real infection. We
studied T cell responses in mice injected with one of
several peptides to which the T cell receptor binds more or
less strongly. Contrary to expectations, we found that the
peptide that interacted most strongly with the T cell
receptor did not provoke the strongest T cell response.
This may be nature’s way of preventing harmful inflam-
matory damage due to excessively strong T cell activation.
Our work shows that peptides that bind the T cell receptor
with medium strength may be best to use for vaccines.
Current vaccine strategies seeking to design peptides that
bind with maximum strength to the T cell receptor may
need to be reconsidered in light of our findings.
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Figure 1. Kinetic parameters of the interaction of the 5C.C7
TCR with four peptide/I-E
k ligands. (A) Surface plasmon resonance
at 25uC was used to study the interaction of varying concentrations of
soluble 5C.C7 TCR with the indicated immobilized peptide/I-E
k
complexes as described in Materials and Methods. The concentration
of soluble TCR resulting in each RU trace is indicated on the MCC/I-E
k
plot, and applies to the corresponding traces on the K3/I-E
k and K5/I-E
k
plots. (B,C) Comparison of all four peptide/I-E
k complexes is shown at
7.1 mM and 14.3 mM TCR, respectively. Association (ka) and dissociation
(kd) constants were calculated as described in Materials and Methods
and are shown in Table 1. (D) Dissociation of PE-labeled H2-I-E
k
tetramers bearing the indicated peptides from naı ¨ve 5C.C7 RAG2-
deficient T cells was done at 25uCo r3 7 uC. TCR/pMHC tetramer half-lives
were calculated from linear regressions and are shown at the end of
each line and in Table 1.
doi:10.1371/journal.pbio.1000481.g001
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k complexes have a slower off-rate than K3/I-E
k
complexes, which corresponds to a half-life nearly twice as long
(6.3 versus 3.4 s; see Table 1). K5/I-E
k complexes have the slowest
off-rate, which results in a longer half-life than MCC/I-E
k
complexes (9.1 versus 6.3 s; see Table 1). KD values (resulting
from kd/ka) for MCC/I-E
k and K5/I-E
k are similar (43.5 and
42.4 mM, respectively), while that for K3/I-E
k complexes
(165 mM) indicates a lower monomeric binding affinity at 25uC
(Table 1).
To examine the binding of the various pMHC ligands to 5C.C7
TCR in the context of live T cells, we measured the half-life of
tetramer binding to naı ¨ve transgenic 5C.C7 T cells using PE-
labeled I-E
k tetramers bearing the weak agonist peptide 102S
[19,20], the agonist peptides MCC and K3 [24], and the
superagonist peptide K5 [22–24], as described in Materials and
Methods (Figure 1D, Table 1). At 25uC (Figure 1D, left panel),
102S/I-E
k tetramers have the shortest half-life of TCR binding
(33s), consistent with the inability to measure the interaction by
SPR (Figure 1A) or by tetramer dissociation at 37uC (Figure 1D,
right panel). K3/I-E
k tetramers have a shorter half-life of tetramer
binding than MCC/I-E
k tetramers at both 25uC and 37uC. K5/I-
E
k tetramers have the longest half-life of 5C.C7 TCR binding,
consistent with the kd and half-life derived by SPR (Table 1). The
difference between K5/I-E
k and MCC/I-E
k tetramer dissociation
is greatest at 37uC, with K5/I-E
k tetramers binding almost twice
as long (Figure 1D, right panel). The half-lives of TCR/pMHC
binding derived by tetramer dissociation are greater than those
from SPR (Table 1), consistent with the interaction of multivalent
versus monovalent pMHC complexes, but there is good
agreement between the two methods when comparing relative
off-rates of the various pMHC ligands (Figure S1), in accordance
with previously published data [24,26].
Although the SPR-derived KD value for the binding of 5C.C7
TCR to monomeric K5/I-E
k complexes is only slightly lower than
that for MCC/I-E
k (Table 1), the K5/I-E
k tetramer stains naı ¨ve
5C.C7 T cells more brightly at equilibrium (Figure S2A). As
described in Materials and Methods, titrations of the tetramers at
equilibrium were done as part of apparent KD analysis (Figure
S2B,C) [27], which shows that K5/I-E
k tetramers bind to 5C.C7
T cells with relatively higher avidity than MCC/I-E
k tetramers.
The larger difference in the equilibrium K5 and MCC
measurements seen with tetrameric pMHC and T cells (Figure
S2) versus solution measurements with monomeric pMHC and
TCR (Figure 1, Table 1) could be explained by a greater effective
affinity due to the two-dimensional confinement imposed by the T
cell membrane [28–30]. kd is likely to be the more important
determinant of pMHC ligand potency in this case [10], especially
given the small association rates of the 5C.C7 TCR/pMHC
complexes (ka ,10
3 M
21s
21; Table 1) [13]. Taken together, the
data indicate that the interaction of 5C.C7 TCR with K5/I-E
k
complexes is stronger than with MCC-I-E
k.
Consistent with previously published data showing that fewer
K5/I-Ek complexes are needed to induce calcium flux in 5C.C7 T
cells [22,23], K5 peptide is a more potent inducer of T cell
activation in vitro (Figure 2). Naı ¨ve 5C.C7 T cells were stimulated
with splenocytes pulsed in vitro with the various peptides, and
proliferation was assessed by incorporation of
3H-thymidine
(Figure 2A). Approximately four times as much 102S peptide
and half as much K5 peptide, on average, is needed to induce the
same amount of T cell proliferation as the natural ligand MCC (in
vitro EC50, Table 1), which reflects their previous characterization
as weak agonist and superagonist, respectively [19–23]. K3
peptide seems to activate 5C.C7 T cells better than its half-life
would suggest (Table 1), which could be analogous to results
previously described for the related cytochrome c-reactive 2B4
TCR, in which K3 binding induced a heat capacity change that is
potentially indicative of structural rearrangements that contribute
to T cell activation potency [24]. We also activated naı ¨ve 5C.C7 T
cells in vitro with DCs purified from the spleens of B10.A mice
immunized with the various peptide ligands (Figure 2B–D), which
shows that APCs pulsed with K5 peptide in vivo are the most
potent stimulators of 5C.C7 T cells in vitro (see below).
Diminished In Vivo T Cell Responses to High-Avidity TCR
Stimulation
In vivo activation of small numbers of adoptively transferred
5C.C7 T cells by immunization with MCC peptide and LPS
reproducibly results in T cell expansion, contraction, and
maintenance (Figure 3) [31]. At the peak of the expansion (6–
7 d after immunization) the 5C.C7 T cells represented up to 8% of
CD4
+ T cells in peripheral blood, and after contraction were
maintained at 1%–2% of blood CD4
+ T cells (Figure 3B). When
Table 1. In vitro properties of 5C.C7 TCR ligands.
Peptide
Ligand Sequence
a
Ligand Affinity
for I-E
k IC50 (nM)
b
ka
(M
21s
21)
c
kd
(s
21)
c
KD
(mM)
c
Monomer
tK (25uC) (s)
d
Tetramer
tK (25uC) (s)
d
Tetramer
tK (37uC) (s)
d
In Vitro
EC50 (nM)
e
102S ANERADLIAYLKQASK 11364n d
f nd
f nd
f nd
f 3360.4 nd
f 160.3
K3 ANERADLIAYPKAATKF 9062 1,2306236 0.20360.00344 165 3.4 124.663.5 17.361.2 24.87
MCC ANERADLIAYLKQATK1 0 8 64 2,530694.6 0.1160.00134 43.5 6.3 188.1 31.961.3 37.80
K5 ANERADLIAYFKAATKF 10063 1,810683 0.076660.00108 42.4 9.1 219.4 53.668.3 17.52
aTCR contact residues are underlined and italicized in the MCC sequence.
bThe binding affinity of soluble I-E
k for the various peptides was previously reported in [24]. The IC50 value is the concentration of unlabeled peptide that prevented
50% of biotinylated peptide binding to I-E
k. Errors represent s.d. from the mean.
cValues were derived from SPR measurements obtained with immobilized peptide/I-E
k complexes and soluble 5C.C7 TCR. Data in Figure 1 were fitted to a 1:1 Langmuir
binding model to generate ka and kd.K D was calculated by kd/ka. Errors represent s.d. from the mean and are derived from two independent experiments.
dThe half-life (t1/2) of I-E
k monomer binding to 5C.C7 TCR is equal to ln2/kd.k d was calculated as described in note c. The half-life (t1/2) of I-E
k tetramer binding was
calculated from linear regression plots (Figure 1) as the time at which median tetramer fluorescence was equal to 50% of that at t=0. Errors represent s.d. from the
mean, calculated from three or more independent experiments, except in the case of 102S 25uC (two independent experiments).
eEC50 values were determined as the peptide concentration that yielded 50% of maximal
3H-thymidine incorporation by 5C.C7 RAG22/2 lymphocytes in response to
the indicated peptides presented by B10.A splenocytes (Figure 2A). Values are averaged from four independent experiments.
fNot determined. On- or off-rates were too fast to be measured accurately by SPR (see Figure 1). Thus, the half-life of 102S/I-E
k monomer binding to 5C.C7 TCR cannot be
calculated. The half-life of 102S/I-E
k tetramer binding to 5C.C7 TCR was determined at 25uC but is too short to be measured at 37uC.
doi:10.1371/journal.pbio.1000481.t001
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ligands, we saw that K3 and MCC agonist peptides induced
greater CFSE dilution, peak expansion, and maintenance of
5C.C7 T cells than the weak agonist 102S peptide (Figures 4 and
5), consistent with their greater in vitro potency. Surprisingly, we
found that the in vitro–defined superagonist K5 peptide induced
the accumulation of fewer 5C.C7 T cells than MCC at every
phase of the immune response (Figures 4 and 5). This correlated
with slightly delayed CFSE dilution and decreased proliferative
capacity of K5-stimulated cells at early times after immunization
(Figure 4A,B).
To examine the possibility that high-avidity interactions with
APC make in vivo K5-stimulated 5C.C7 T cells more difficult to
extract during homogenization of lymph node tissue prior to flow
cytometric analysis [32], accounting for the decreased numbers of
5C.C7 T cells in lymph nodes after K5 immunization, we
examined CD45.1 immunofluorescence on cryosections of day 6
lymph nodes from mice immunized with MCC or K5 peptide
(Figure S3). Figure S3A shows five representative images each
from MCC and K5 immunizations. Using Metamorph software,
the number of CD45.1
+ 5C.C7 T cells was estimated within T cell
areas by dividing the total PE fluorescence by the average
individual 5C.C7 T cell area (defined by lack of B220 and CD19
staining) in MCC- or K5-stimulated samples (Figure S3B and
Materials and Methods). The immunofluorescence data are
consistent with the flow cytometry results in Figure 4 and show
that there are fewer K5-stimulated 5C.C7 T cells per mm
2 of T
cell area (Figure S3B). K5-stimulated 5C.C7 T cells appear to
have, on average, a smaller individual cell area than MCC-
stimulated cells (Figure S3C) and less CD45.1 (Figure S3A and D),
which was taken into account as part of the quantitation shown in
Figure S3B.
Upon ex vivo restimulation of CD4
+ T cells from day 6
lymph nodes, 5C.C7 T cells activated with any of the four
peptides produced interleukin-2 (IL-2) and interferon-c (IFN-c)
(Figure 4A,C). For 102S, K3, and MCC peptides, the number of
cytokine-producing 5C.C7 T cells correlates with in vitro ligand
potency; however, fewer K5-stimulated 5C.C7s produced IL-2
and IFN-c when compared to MCC-stimulated cells (Figure 4A,C),
showing that the effector function of K5-stimulated cells is
diminished in addition to proliferation. Thus, fewer 5C.C7 T
cells accumulate in response to immunization with K5 peptide as
compared to MCC peptide, and fewer of those secrete IFN-c in an
ex vivo restimulation assay. The number of IFN-c
+ 5C.C7 T cells
induced in response to immunization with the various ligands is
shown in the lower right panel of Figure 4C. The number of IFN-c
secreting 5C.C7 T cells is 60% reduced in K5-immunized mice,
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Figure 2. K5 peptide is a more potent inducer of in vitro 5C.C7
T cell proliferation than MCC peptide when presented on both
in vitro and in vivo pulsed APCs. (A) Lymph node cells from 5C.C7
TCR transgenic RAG22/2 mice were stimulated with peptide-pulsed
irradiated B10.A splenocytes in the presence of
3H-methyl-thymidine for
60 h. The mean EC50 for each peptide derived from these experiments
is shown in Table 1. B10.A mice, three per peptide group, with (B) or
without (C) adoptively transferred 5C.C7 RAG22/2 T cells, were
immunized with the indicated peptides and LPS, and 2 d later
CD11c+ splenocytes were purified, irradiated, and used to stimulate
naive 5C.C7 RAG22/2 T cells in vitro for 60 h. (D) Titration of
exogenous MCC peptide added to the in vivo–pulsed APCs in (C) (10
5
per well) shows that the APCs are equally capable of presenting
antigen. Data in Figure 2 are representative of at least three
independent experiments. Error bars show mean 6 s.e.m., n=3 wells.
doi:10.1371/journal.pbio.1000481.g002
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Figure 3. Immunization with MCC peptide and LPS results in expansion, contraction, and maintenance of 5C.C7 T cells in vivo. (A)
B10.A mice with adoptively transferred naı ¨ve 5C.C7 RAG22/2 CD45.1 T cells were immunized with LPS alone (‘‘no peptide’’) or LPS+MCC peptide
(‘‘MCC’’). CD4
+CD45.1
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immunization with MCC peptide. The traces of four individual mice are shown.
doi:10.1371/journal.pbio.1000481.g003
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to affect the inflammatory milieu, given that IFN-c is a key
mediator of many aspects of immunity.
No significant differences were found in levels of canonical
activation markers such as CD25, CD62L, and CD44 during the
initial expansion of 5C.C7 T cells in response to the various
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Figure 4. Blunted in vivo responses of 5C.C7 T cells to a high-affinity ligand. Naı ¨ve 5C.C7 RAG22/2 CD45.1 T cells were adoptively
transferred into normal B10.A recipients and activated by immunization with the indicated peptides and LPS. (A) Day 2.5 CFSE plots represent
samples pooled from four or five mice, and number of divisions is indicated at the top of each peak. Frequency of 5C.C7 T cells as a percentage of
total CD4
+ T cells, or frequency of 5C.C7 T cells producing IL-2 or IFN-c, are shown in samples from day 6 lymph nodes on representative flow plots.
(B) Proliferative capacity was calculated from CFSE profiles, and 5C.C7 T cells were quantified as a percentage of total CD4
+ T cells. Because of the low
frequency of 5C.C7 T cells present at day 2.5 it was necessary to combine samples from multiple mice to visualize CFSE profiles and analyze
proliferative capacity. Thus, each bar in the graphs represents samples pooled from four or five mice, and the data are representative of three
independent experiments. (C) Upper left, number of 5C.C7 T cells (normalized to total CD4
+ T cells) in day 6 lymph nodes; the data are pooled from
four independent experiments. Horizontal lines on graphs represent the mean. ***p,0.0001. Upper right and lower left, number of IL-2
+ and IFN-c
+
cells (as a percentage of 5C.C7 T cells). IL-2, *p=0.0104. IFN-c,* p=0.0463. The lower right panel shows the absolute number of IFN-c
+ 5C.C7 T cells
per 1610
7 lymph node CD4
+ T cells. **p=0.0078. Cytokine data are pooled from two independent experiments. Two-tailed p values are from
unpaired t test.
doi:10.1371/journal.pbio.1000481.g004
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memory 5C.C7 T cells initially stimulated with 102S and K5
peptides have a CD62L
lo phenotype (Figure 5B), suggesting that,
in addition to lower numbers of total memory cells in blood
(Figure 5A) and lymph nodes (Figure 5C,D), these peptides may
induce a lower fraction of effector memory cells (TEM) [33–35]
than MCC (although other possibilities exist, see Discussion).
When the resting memory cells generated with the various
peptides were restimulated with MCC peptide, the results were
similar to those in the primary stimulation (Figure S5A,B), which
likely reflects precursor frequency [36]. Similar percentages of
memory cells generated with K5 and MCC peptides are able to
produce IFN-c upon ex vivo restimulation (Figure S5C),
suggesting that the memory cells generated with K5 peptide are
as functional on a per-cell basis as those generated with MCC,
even though they are maintained in lymph nodes at a much lower
frequency (Figure 5C,D). Thus, ligand potency affects the early in
vivo division, accumulation, and cytokine production of a
monoclonal population of CD4
+ T cells. In contrast to what is
predicted from biochemical data, the strong peptide ligand K5
induces a blunted in vivo 5C.C7 response that is of lower
magnitude and function than the wild-type ligand MCC.
K5 pMHC Complexes Are Not Limiting In Vivo
Since endogenous T cells have been shown to compete with
adoptively transferred T cells for cognate pMHC-bearing APCs
[37], we examined responses to the various peptides by MCC/I-E
k
tetramer staining of lymph node cells from B10.A mice (containing
no adoptively transferred 5C.C7 T cells). Seven days after
immunization, we found low percentages of endogenous responder
T cells to all four peptides (,0.1% of total CD4
+ T cells; Figure
S6). A more competitive endogenous response is therefore unlikely
to be the explanation for the decreased responses of 5C.C7 T cells
to K5 peptide in vivo. Also, titration of peptides in vivo showed
that there was no peptide dose at which K5 peptide induced more
proliferation than MCC (unpublished data).
We addressed potential differential in vivo antigen persistence
by injecting MCC or K5 peptide at various times prior to transfer
of CFSE-labeled 5C.C7 T cells (Figure S7). In this experiment, the
extent of division of the transferred T cells serves as a readout of
amount of antigen present. The data show that MCC and K5
peptides persist equally and for a few weeks in vivo. We then
considered the possibility that the blunted responses were
occurring because the amount of K5 pMHC complexes was
limiting in vivo. In order to directly examine the stimulatory
function of in vivo–pulsed APCs, we used irradiated splenic DCs
isolated from mice immunized with the different peptides to
activate naı ¨ve 5C.C7 T cells in vitro, without the addition of
exogenous peptide (Figure 2B,C). The rank order of T cell
activation potency of the peptides in this assay was the same as in
the in vitro proliferation assay shown in Figure 2A, which
demonstrates that presentation of K5 peptide is not diminished in
vivo. Transfer of 5C.C7 T cells does not affect the results of the
experiment (Figure 2B). These results also show that K5 pMHC
complexes assembled in vivo are high avidity 5C.C7 T cell ligands
and that the blunted in vivo responses to K5 peptide are not due to
attenuation of APC maturation or function, since the APCs from
mice immunized with K5 peptide are equally capable of
presenting antigen (Figure 2D). Thus, the diminished responses
to K5 peptide in vivo are not recapitulated in vitro when in vivo–
pulsed APCs are used, which suggests that T cell activation is
attenuated at some point after initial high-avidity ligand
recognition in vivo. Indeed, at early time points after activation,
5C.C7 T cells stimulated in vivo have higher levels of CD5 (Figure
S4B), which is consistent with their experience of a stronger TCR
signal in vivo [38–41].
We also did not find evidence that the blunted responses to K5
peptide are due to preferential suppression of the 5C.C7 effector T
cells by regulatory T cells. When CD4
+CD25
+Foxp3
+ cells were
depleted by injection of anti-CD25 antibody (Figure S8), numbers
of MCC- and K5-stimulated 5C.C7 T cells in lymph nodes at the
peak of the response are indistinguishable from controls (Figure
S5E). The levels of regulatory T cell depletion observed after
injection of anti-CD25 antibody (one third of initial levels in lymph
nodes; Figure S8D) are sufficient to significantly enhance tumor-
reactive T cell responses in mice [42,43]. Subcutaneous immuni-
zation with K5 peptide in the presence of LPS does not result in
expression of Foxp3 by 5C.C7 T cells (Figure S9). This is in
contrast to what we observe during intravenous injection 5C.C7 T
cell ligands in the absence of LPS [44]. In summary, the lower
capacity for expansion, cytokine production, maintenance, and
effector memory differentiation displayed by the K5-stimulated
cells is not explained by competitive K5-reactive endogenous T
cell responses, antigen dosage or persistence effects, lower in vivo
stability of the K5 peptide (or pMHC complexes), or enhanced
suppression of high-avidity T cell responses by regulatory T cells.
In Vivo, K5-Stimulated 5C.C7 T Cells Have Decreased
Levels of Phosphorylated Signaling Intermediates
Compared to Those Stimulated with MCC
When we further investigated the phenotype of K5-stimulated
5C.C7 T cells, we found no evidence of clonal exhaustion as
defined by increased expression of PD-1 (Figure 6A) or increased
*
0 5 10 15
0
1
2
3
4
102S
K3
MCC
K5
no peptide
30 60 90
days after immunization
*
c
e
l
l
s
13 54
58 39
102S K3
MCC K5
CD4+CD45.1+:
CD62L
A
0.0
0.2
0.4
day 31
0.0
0.2
0.4 day 59
B
C D
*** ***
Figure 5. Fewer K5-stimulated 5C.C7 T cells are found at the
peak, contraction, and maintenance phases of the response.
5C.C7 T cells were adoptively transferred and activated as in Figure 3,
and blood samples were analyzed for CD4
+ CD45.1
+ cells at the
indicated time points (A). Number of 5C.C7 T cells expressed as a
percentage of total CD4
+ T cells is shown. Error bars show mean 6 s.d.
Day 6, *p=0.0247, n= 5 .D a y9 0 ,* p=0.0257, n=5. Data are
representative of two independent time courses. (B) shows CD62L
staining of day 59 5C.C7 T cells from lymph nodes. Number of 5C.C7 T
cells in lymph nodes is shown at day 31 (C, ***p,0.0001) and day 59 (D,
***p,0.0001). Two-tailed p values are from unpaired t test. Data in (B),
(C), and (D) are representative of two or more independent
experiments.
doi:10.1371/journal.pbio.1000481.g005
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cells. In addition, the possibility that K5-stimulated 5C.C7 T cells
divide more rapidly than MCC-stimulated cells and are subse-
quently deleted [45] is not consistent with the delay in CFSE
dilution exhibited by K5-stimulated cells at early time points
(Figure 4A). Taken together, these results indicate that K5-
stimulated 5C.C7 T cells are not likely to be abortively over-
activated in vivo.
Our data suggest that T cell responses to high-avidity ligands
are attenuated in vivo. CTLA-4 is a well-characterized negative
regulator of T cell activation that has been suggested to
preferentially restrict T cell responses to strong TCR signals
[46]. However, we found no evidence that inhibition by CTLA-4
is involved in the blunted T cell responses we observe to K5
peptide in vivo (E.C. and J.P.A., manuscript in preparation).
To gain insight into the molecular mechanisms of attenuation
that occur in response to stimulation with K5 peptide, we fixed
lymph nodes immediately after sacrifice (60 h after immuniza-
tion) and analyzed the in vivo activated 5C.C7 T cells for
levels of phosphatases and phosphorylated signaling intermediates
(Figure 6C and Figures S10 and S11). The SH2-domain
containing tyrosine phosphatase (SHP-1) is thought to participate
in a negative feedback loop that functions in TCR ligand
discrimination [47], but we did not observe significant differences
in levels of either SHP-1 or phosphorylated ERK between MCC-
and K5-stimulated cells at the time points examined (Figure S10).
This could be because regulation of TCR ligand discrimination by
SHP-1 levels is restricted to the boundary between low-affinity
agonists and non-agonists/antagonists, as has been suggested [48].
We also did not detect increased levels of the lipid phosphatase
PTEN, which negatively regulates the PI3 kinase pathway [49], in
K5-stimulated 5C.C7 T cells (Figure S10).
Strikingly, when the in vivo–activated 5C.C7 T cells were
analyzed for levels of S473-phosphorylated Akt (pAkt), which
reflects optimally active Akt kinase [50], and phosphorylated Stat3
(pStat3), which is induced in response to multiple cytokines [51]
(Figure 6C, Figure S11), fewer K5-stimulated 5C.C7 T cells were
positive for pAkt and pStat3, compared to MCC-stimulated cells
(Figure 6C). The decreased amounts of signaling intermediates in
two important pathways in the K5-stimulated 5C.C7 T cells
suggest that their activation state is negatively regulated on an
intracellular level in response to high-avidity TCR stimulation in
vivo. Upon in vitro stimulation, more K5- than MCC-stimulated
5C.C7 T cells are positive for pAkt and pStat3 (Figure S12),
consistent with the greater in vitro potency of K5 peptide
(Figure 2). These results reveal a clear difference between the in
vivo and in vitro regulation of the T cell response to a high-avidity
ligand.
Discussion
In contrast to the assumption that more potent T cell responses
result from higher-avidity TCR recognition, here we report
diminished T cell responses to a strong TCR ligand in vivo. We
studied the in vivo activation of 5C.C7 T cells by immunization
with LPS and a panel of peptides with a range of in vitro T cell
activation potency, which results in fully functional effector and
memory responses. Interestingly, we observed optimal T cell
responses to the peptide ligands with intermediate TCR/pMHC
half-lives. Contrary to what is predicted from in vitro data, the K5
ligand, which has the longest TCR/pMHC half-life, induces less
in vivo division, accumulation, cytokine production of 5C.C7 T
cells during the effector phase of the response, as well as
persistence of fewer 5C.C7 T cells during the memory phase.
Given that we observe fewer CD62L low memory cells in lymph
nodes after immunization with K5 peptide, we cannot rule out
that K5 favors TEM development and greater homing to tissues
[34], thus accounting for the fewer numbers of memory 5C.C7 T
cells in lymph nodes prior to exit (Figure 5B). The data in
Figure 5B would also be consistent with accelerated TCM
development, or even impaired TEM development if the CD62L
low population present in the MCC response is considered to be
lymph node TEM cells (Figure 5B). Increased TEM development
and tissue homing induced by K5 peptide could potentially
account for the decreased numbers of K5-stimulated T cells at
later time points, but it is unlikely that it could explain the delayed
CFSE dilution and decreased accumulation in lymph nodes at the
peak of the primary response, observed at day 2.5 and day 6,
respectively (Figure 4 and Figure S4C), especially given the lack of
evidence for increased egress of K5-stimulated cells into the blood
at these earlier time points (Figure 5).
We found that the blunted response to K5 peptide is not due to
a lack of in vivo availability of peptide/MHC complexes, dose
effects, or competition by endogenous responses. In addition, the
pAkt (S473) pStat3 (Y705)
MCC
K5
c
e
l
l
s
c
e
l
l
s
CD45.1
a
n
n
e
x
i
n
 
V
PD-1
c
e
l
l
s
A
B
9.1
5.7
50.6
27.7
52.9
22.9
CD4+CD45.1+
day 6 day 2.5
MCC
K5
MCC
K5
day 2.5 day 6
28.6
40.7 102S
6.9
CD4+CD45.1+:
no peptide
102S
K3
MCC
K5
0
1000
2000
3000
M
F
I
P
D
-
1
C
Figure 6. In vivo activation status of 5C.C7 T cells stimulated
with the high-affinity ligand K5 peptide. Naı ¨ve 5C.C7 RAG22/2
CD45.1 T cells were adoptively transferred and activated by immuni-
zation with the indicated peptides and LPS. (A) Lymph node CD4
+ T
cells were stained for PD-1 at day 2.5 and day 6 (CD4
+CD45.1
+ gated).
The day 2.5 histograms represent samples pooled from four or five
mice. The black histogram corresponds to cells stimulated with LPS
alone. Graphed PD-1 MFIs are from day 6, error bars show mean 6 s.d.,
n=3 mice. (B) Annexin V staining on CD4
+ T cells from day 6 lymph
nodes. (C) Day 2.5 lymph node samples were fixed immediately after
harvest, methanol permeabilized, and stained with antibodies to
phosphorylated Akt (S473) and phosphorylated Stat3 (Y705). Histo-
grams are gated on CD4
+CD45.1
+ cells and represent samples pooled
from four or five mice. Percent of 5C.C7 T cells positive for annexin V,
pAkt, or pStat is shown on the plots and histograms. The data are
representative of three independent experiments.
doi:10.1371/journal.pbio.1000481.g006
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signs of apoptosis or clonal exhaustion, making it unlikely that they
are abortively over-activated. Finally, the K5-stimulated 5C.C7 T
cells are not preferentially inhibited by regulatory T cells or by the
T cell inhibitory receptor CTLA-4. Interestingly, we observed
attenuation at the level of intracellular signaling intermediates
associated with Akt kinase activation and cytokine signaling, which
we measured directly ex vivo using antibodies to pAkt and pStat3.
Fewer K5-stimulated 5C.C7 T cells were positive for pAkt,
indicating decreased activity of the mammalian target of
rapamycin (mTOR)-containing complex mTORC2 in these cells
[50]. We also observed fewer pStat3-positive K5-stimulated 5C.C7
T cells, which may indicate that the cells are less responsive to
cytokines which activate the Stat3 pathway [51].
In a recent study of in vivo CD8
+ T cell activation, in vitro
ligand potency correlated with the magnitude of the in vivo T cell
response, i.e. the highest-affinity ligand (which was the natural
OT-1 ligand SIINFEKL) induced the most robust response [25].
The reason we observed attenuation at the high end of the ligand
potency spectrum may be because we were able to examine T cell
responses to a superagonist peptide, which possibly exceeds a
ligand potency threshold at which T cell attenuation is observed.
Attempts to find other strong 5C.C7 TCR ligands, which would
facilitate examination of this hypothesis, have been unsuccessful
thus far. It is also possible that the attenuation we observed in vivo
in response to high-avidity TCR stimulation is unique to CD4
+ T
cell responses.
The effect of adjuvant upon the avidity of TCRs in the
polyclonal CD4
+ T cell response to pigeon cytochrome c (PCC)
protein was recently examined by Malherbe et al. [52]. These
authors found that immunization in the presence of non-depot
forming adjuvants containing toll-like receptor 4 or 9 agonist
resulted in accumulation of high-avidity PCC-reactive T cells at
the peak of the response, based on their previous characterization
of the avidity of TCRs bearing specific CDR3 sequences [53], as
well as levels of pMHC II tetramer binding. The presence of high-
avidity CD4+ T cell clones in the Malherbe et al. study is not
inconsistent with attenuation of the monoclonal CD4
+ T cell
population that we tracked in response to strong TCR ligand. It is
hard to compare the avidities of the responding TCRs since both
the TCRs and the peptide ligands in question are different.
Therefore, it is possible that the responses to the strongest ligand in
our study exceeds an avidity threshold beyond which T cell
attenuation occurs, and that this threshold is not reached by any of
the TCRs in the Malherbe et al. study. It is also possible that the
naı ¨ve repertoire in the Malherbe et al. experiments contains T
cells with even higher avidity for PCC antigen than the clones
favored by immunization with the TLR agonists. These clones
may then be attenuated in response to high-avidity TCR
engagement, such as we observed in our study. This could result
in the underrepresentation of such clones at the peak of the
primary response, and thus they may not be present during the
CDR3 sequence analysis performed by Malherbe et al. [52].
At the low potency end of the ligand spectrum, our results were
in agreement with the CD8
+ T cell study mentioned above [25];
the lowest affinity ligand we examined (102S) was able to induce a
functional response. Interestingly, we saw that the lower-
magnitude T cell response induced by 102S correlates with low
levels of pAkt and pStat3 before the expansion phase; however, it
is possible that the accumulation of these phosphorylated
intermediates occurs at a later time in response to the weak
agonist peptide [54]. The observation of sustained signaling
intermediates such as pAkt in the in vivo T cell response to antigen
is not necessarily predicted by in vitro studies [55] and may point
to the importance of the cumulative activity of signaling pathways
in defining the magnitude of in vivo T cell responses. Thorough
examination of the timing of engagement and sustained activity of
signaling pathways downstream of in vivo T cell activation is likely
to lend further insight into such questions, as well as the
biochemistry of in vivo T cell activation in general.
We propose that negative regulation of the extent of T cell
activation occurs in response to high-avidity in vivo TCR
stimulation, potentially in the context of the long-lived T cell-
DC contacts that are a hallmark of in vivo antigen recognition
[56], and that this is characterized by but not necessarily limited to
a decrease in the phosphorylated signaling intermediates we
measured in this study. Although we did not find increased levels
of the inhibitory phosphatases SHP-1 and PTEN in the K5-
stimulated cells, cell-intrinsic attenuation of activation could be
certainly mediated by other intracellular negative regulators of
TCR signaling [57] and/or increased internalization and
degradation of cell surface receptors [58] in response to strong
sustained in vivo TCR engagement. We did not observe increased
TCR downregulation by K5-stimulated cells (unpublished data).
The strong in vivo TCR signal could also influence (directly or
indirectly) induction of or responsiveness to cytokines, resulting in
attenuated T cell responses. Although we did not find a role for
regulatory T cells in the blunted response to K5 peptide in
experiments where CD4
+CD25
+Foxp3
+ cells were depleted by
injection of anti-CD25 antibody (Figure S8), nor did we observe
Foxp3+ induction by 5C.C7 T cells in response to subcutaneous
immunization with K5 (Figure S9), other cell-extrinsic mecha-
nisms of attenuation cannot be excluded.
Attenuation of in vivo T cell responses to high-avidity pMHC
ligands may function to prevent detrimental inflammatory effects
that could occur in response to high-avidity TCR recognition of
either self or foreign peptides. Our results are contrary to the
common assumption that higher-avidity TCR recognition pro-
motes a more potent T cell response and point to an upper limit of
T cell ligand potency in vivo. Interestingly, a study of a panel of
peptide ligands with variable affinity for a tumor-reactive TCR
showed that elicitation of the most potent tumor-reactive CD8
+ T
cells in vivo and the best tumor-free survival occurred after
vaccinationwithpeptideligands thatdisplayed intermediateaffinity
and in vitro T cell activation potency [11]. Although it is unclear if
the tumor-reactive T cells in vivo bear the same TCR as the clone
on which ligand affinity was characterized, the results point out an
important discrepancy between the in vitro and in vivo efficacy of
TCR ligands. This discrepancy, along with the attenuation we
observed in vivo while tracking the responses of monoclonal CD4
+
T cells to a strong ligand, suggests that vaccination strategies that
aim to elicit maximum-avidity TCR recognition with engineered
peptide ligands may warrant reconsideration [11].
Materials and Methods
Ethics Statement
All mice were maintained in microisolator cages and treated in
accordance with NIH and the American Association of Labora-
tory Animal Care regulations. Experiments in this study were
approved by the Memorial Sloan-Kettering Cancer Center
Institutional Animal Care and Use Committee.
Purification of Soluble 5C.C7 TCR and SPR
Coding regions for the 5C.C7 TCR a and b chains were cloned
by PCR into a modified version of the transfer vector pACGP67A
(Pharmingen), which placed the 5C.C7 a and b in frame with
c-jun (a) and c-Fos (b) heterodimerization motifs. Both chains were
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cleavable site. TCR was expressed in insect cells as previously
described [23], isolated from the supernatant by Ni-NTA
purification, cleaved with 3C protease, and further purified by
ion-exchange and size exclusion chromatography. Protein con-
centration was determined using an extinction coefficient (280 nm)
of 1.3 ml?mg
1?cm
1. All SPR data were collected at 25uC using a
BIAcore 3000
TM instrument (BIAcore Inc.). Purified biotinylated
pMHC complexes were immobilized on a streptavidin chip
(BIAcore Inc.) to a level of 250–500 RU. Free biotin-binding sites
were blocked with 10 mM biotin. Binding of 5C.C7 TCR was
measured in PBS, pH 7.8 with 0.005% Surfactant P20 (BIAcore
Inc.) by injecting a range of concentrations (0.9–14.3 mM) at a
flow-rate of 30 ml/min. All data were background subtracted using
a biotin-blocked streptavidin surface as a reference surface. Data
were fitted to a Langmuir binding model using global fitting
(Biaevaluation, BIAcore Inc.) to calculate ka and kd constants. To
prevent aggregation artifacts, all proteins were purified no more
than 12 h before analysis without subsequent concentration steps.
Mice
5C.C7 TCR transgenic RAG22/2- mice were purchased from
Taconic Farms and bred to B10.A CD45.1 (provided by W. Paul
via the NIAID contract facility at Taconic Farms) to generate
5C.C7 RAG22/2 CD45.1 mice, which were used as donor cells
in adoptive transfer experiments. Male B10.A recipient mice were
purchased from Taconic and were used to initiate experiments at
6–9 wk of age.
Tetramers, Tetramer Dissociation, and Apparent KD
Analysis
Tetramer production, dissociation assays, and data analysis
were done as described [27]. Briefly, PE-labeled I-E
k tetramers
with MCC and variant peptides were produced. Naı ¨ve 5C.C7 T
cells were incubated with tetramers (50 mg/mL) for 2 h at RT in
the presence of fresh 0.2% NaN3, equilibrated to 37uCo r2 5 uC,
and measurement of dissociation was initiated with the addition of
anti-I-E
k antibody. Aliquots were removed in 10–20 s intervals
and fixed immediately in 1% PFA. Levels of tetramer staining
were assessed by flow cytometry. Apparent KD analysis was done
as previously described [27]. Briefly, varying concentrations of
tetramers were used to stain the 5CC7 T cells as described above,
and the median intensity of tetramer staining was subjected to
Scatchard analysis. Since tetramers were always in excess, free
tetramer concentration is equal to staining concentration.
Cell Culture and In Vitro T Cell Activation
Cells were cultured in a 37uC humidified chamber with 5% C02
in complete RPMI1640 (supplemented with 10% FCS, 2 mM
glutamine, 100 U/mL penicillin and streptomycin, 2 mM2 -
mercaptoethanol). Single-cell suspensions were prepared from
lymph nodes harvested from 5C.C7 RAG2-deficient mice
(routinely .90% Va11+Vb3+ by flow cytometry) and stimulated
in triplicate in 96-well round-bottom plates with irradiated (2,000
rad) B10.A splenocytes and the indicated peptides for 60 h.
Proliferation was monitored by the addition of
3H-methyl-
thymidine (1 mCi/well). Cells were harvested onto glass-fiber
filters using a Tomtec harvester, and filters were counted using a
MicroBeta scintillation counter (Perkin-Elmer).
Peptides and LPS
Peptides were synthesized and HPLC-purified ($95%) by
Biosynthesis,Inc.(Lewisville,TX).PurifiedLPSwasfrom Invivogen.
Flow Cytometry and Antibodies
Flow cytometry was done on a BD LSRII and data were
analyzed with Flowjo software (Treestar). Antibodies to surface
markers were from BD Pharmingen, eBioscience, or BioLegend.
Antibodies to phospho-Akt, phospho-Stat, phospho-Erk, and
PTEN were Alexa 647 conjugates from Cell Signaling Technol-
ogy. SHP-1 antibody was from Santa Cruz Biotechnology.
In Vivo T Cell Activation
1–5610
4 5C.C7 RAG22/2 CD45.1 T cells were transferred
into B10.A recipients by tail vein injection, and the mice were
immunized the next day with 20 mg peptide and 10 mg LPS at two
sites on either side of the base of the tail. In some experiments the
cells were CFSE-labeled prior to transfer. Proliferative capacity
was calculated from CFSE profiles as described [59]. Total lymph
nodes were pooled for all experiments. Cytokine production was
assessed by ex vivo restimulation for 4–5 h with B10.A DCs and
peptide and intracellular cytokine staining using BD Biosciences
reagents.
Immunofluorescence
5C.C7 RAG22/2 CD45.1 T cells were activated in vivo as
described above. Six days after immunization with MCC or K5
peptide (5 mice per peptide), mice were sacrificed and the lymph
nodes were embedded directly into OCT and frozen using dry ice
and methanol. After temporary storage at 280uC, 10 mm sections
were cut through the entire block (containing 50 lymph nodes)
using a Leica Cryostat and stained with anti-CD45.1-biotin/
streptavidin-PE to mark 5C.C7 T cells and anti-B220-FITC and
anti-CD19-FITC to mark B cell areas. The stained sections (each
containing 10 or more lymph nodes) were scanned with a Mirax
slide scanner (epifluorescence). The number of 5C.C7 T cells was
quantified from the T cell areas of 20 independent lymph nodes
using Metamorph software. Total fluorescence was divided by the
average individual T cell area to estimate the number of 5C.C7 T
cells per mm
2 of T cell area.
CD4+ Purification from Lymph Node Suspensions
To enrich for 5C.C7 T cells originating from low precursor
frequency before flow cytometry, CD4+ T cells were purified from
lymph node suspensions by Dynal negative selection (Invitrogen).
Analysis of Phospho-Intermediates
Lymph node suspensions were fixed immediately after harvest
and then negatively selected for CD4+ T cells. After staining with
antibodies to CD4 and CD45.1, cells were permeabilized with
methanol and stained with phospho-antibodies.
In Vivo–Pulsed APCs
CD11c
+ cells were purified by positive selection (Miltenyi) from
spleens of mice adoptively transferred and immunized as described,
irradiated, and used to stimulate naı ¨ve5C.C7 RAG22/2 T cells in
vitro. Proliferation was assessed by
3H-thymidine incorporation as
described.
Statistical Analysis
Data were analyzed for significance using unpaired Student’s t
test analysis with Prism software.
Supporting Information
Figure S1 Correlation of 5C.C7 TCR/peptide-I-E
k half-
life derived by tetramer dissociation and SPR. Plot of the
TCR Ligand Potency and In Vivo T cell Responses
PLoS Biology | www.plosbiology.org 9 September 2010 | Volume 8 | Issue 9 | e1000481half-life of interaction of purified 5C.C7 TCR with I-E
k
complexed with K3, MCC, and K5 peptides derived by SPR
(Figure 1A–C) versus the half-life derived by tetramer dissociation
(Figure 1D).
Found at: doi:10.1371/journal.pbio.1000481.s001 (0.45 MB EPS)
Figure S2 K5/I-E
k tetramers interact more strongly
with 5C.C7 T cells by equilibrium tetramer staining and
apparent KD analysis. (A) Naive 5C.C7 T cells were stained
for 2 h at 25uC with the indicated I-E
k tetramers (50 mg/mL).
*p=0.0190. Data are representative of three independent
experiments and error bars show mean 6 s.d. (B) Scatchard plot
of tetramer binding at varying concentrations of tetramer,
expressed in nM. Apparent KD analysis was done as described
in Materials and Methods and [27]. Data are representative of two
independent experiments, KD values from which are shown in (C).
*p=0.0364. Two-tailed p value is from unpaired t test.
Found at: doi:10.1371/journal.pbio.1000481.s002 (0.82 MB EPS)
Figure S3 Immunofluorescence of 5C.C7 T cells in
lymph nodes 6 d after immunization with MCC or K5
peptide. B10.A mice adoptively transferred with CD45.1
+ 5C.C7
RAG22/2 T cells were immunized with LPS and MCC or K5
peptide as described in Materials and Methods. Six days later,
lymph nodes were embedded in OCT, frozen, sectioned, stained,
and imaged as described in Materials and Methods. (A) Five
representative images from the lymph nodes of MCC- and K5-
immunized mice are shown. B cells are green and 5C.C7 T cells
are red. The number of 5C.C7 T cells in T cell areas was
quantitated as described in Materials and Methods. The data
comprise analysis of the T cell areas from 20 independent lymph
nodes per peptide, randomly sampled from 50 lymph nodes and
five independent mice per peptide. (C) Area measurements of
individual 5C.C7 T cells stimulated with MCC or K5 peptide. (D)
The dim aCD45.1 immunofluorescence staining apparent in the
lymph nodes of K5-stimulated mice is consistent with that seen
during flow cytometric analysis. The graph shows the MFI (by flow
cytometry) of CD45.1 from day 6 lymph node samples and
represents 12 independent mice per peptide. Two-tailed p values
are from unpaired t test.
Found at: doi:10.1371/journal.pbio.1000481.s003 (7.04 MB TIF)
Figure S4 Phenotype of in vivo stimulated 5C.C7 T cells.
(A) B10.A mice with adoptively transferred CD45.1
+ 5C.C7
RAG22/2 T cells were immunized with indicated peptides and
LPS, and CD4
+ T cells from lymph node were analyzed 2.5 d
after immunization. Each plot represents samples pooled from
three to five mice. Percent of CD25
+ or CD62Llo (of
CD4
+CD45.1
+ cells) is shown on plots. (B) CD5 levels on 5C.C7
T cells 2.5 d after immunization. Each histogram and bar
represent samples pooled from three to five mice. (C) Lymph
node samples analyzed at day 6. Error bars show mean 6 s.d.,
n=3 mice.
Found at: doi:10.1371/journal.pbio.1000481.s004 (2.88 MB EPS)
Figure S5 Reactivation of resting lymph node 5C.C7 T
cells. B10.A mice with adoptively transferred CD45.1
+ 5C.C7
RAG22/2 T cells were immunized with indicated peptides and
LPS. (A) PBLs 45 d later immunization. *p=0.0332, n=4. (B) The
mice in (A) were all reimmunized with MCC peptide and LPS,
and lymph node CD4
+s were analyzed 4 d later. **p=0.0061,
n=4. (C) Lymph node CD4
+s from the mice in (B) were
restimulated ex vivo with DCs and MCC peptide and stained
for intracellular IFN-c. Two-tailed p values are from unpaired
t test.
Found at: doi:10.1371/journal.pbio.1000481.s005 (0.59 MB EPS)
Figure S6 Endogenous responses to MCC and related
variant peptides. B10.A mice were immunized with the
indicated peptides and LPS, and lymph node cells were stained
with PE-MCC/I-E
k tetramer 7 d later. (A) Plots are gated on
CD4
+CD44
hiB220-propidium iodide. Percent of tetramer
+ cells (of
CD4
+ T cells) is shown on plots and graphed in (B). Horizontal
lines on the graph represent the mean. (C) Mean fluorescence
intensity of tetramer in gated populations. Error bars show mean
— s.d., n=3 mice. The data are representative of two independent
experiments.
Found at: doi:10.1371/journal.pbio.1000481.s006 (1.81 MB EPS)
Figure S7 MCC and K5 peptides persist equally in vivo.
B10.A mice were immunized with the indicated peptides at 4, 2, 1,
and 0 wk before adoptive transfer of CFSE-labeled 5C.C7 T cells.
5C.C7 T cell division was analyzed at 48 h after transfer as a
measure of peptide antigen persistence over time. All histograms
are gated on CD4
+CD45.1
+ 5C.C7 T cells. Data shown are
representative of two mice per condition and two experiments.
Found at: doi:10.1371/journal.pbio.1000481.s007 (0.99 MB EPS)
Figure S8 No evidence of a role for regulatory T cells in
blunted responses to K5 peptide in vivo. B10.A mice were
injected intraperitoneally with 0.5 mg aCD25 antibody (clone
PC61) to deplete regulatory T cells, or 0.5 mg rat IgG as a control.
(A,B) Three days later, mice were bled and PBLs were analyzed
for CD4
+CD25
+Foxp3
+ cells to confirm depletion, and adoptively
transferred with 5C.C7 T cells. (C,D) Analysis of CD4
+Foxp3
+
cells in lymph node samples 10 d after depletion shows decreased
amounts of regulatory T cells persist throughout the course of the
experiment. (E) Seven days after immunization with either MCC
or K5 peptide (11 d after injection of PC61), CD45.1
+ 5C.C7 T
cells were quantified in lymph node samples. Data are represen-
tative of three independent experiments.
Found at: doi:10.1371/journal.pbio.1000481.s008 (1.84 MB TIF)
Figure S9 Subcutaneous immunization with peptide
and LPS does not induce Foxp3 expression in 5C.C7 T
cells. B10.A mice containing adoptively transferred CD45.1
+
5C.C7 T cells were immunized subcutaneously with LPS+the
indicated peptide. Six days after immunization, Foxp3 expression
was assessed in lymph node samples by flow cytometry. Each
histogram represents an individual mouse, and the experiment
shown is representative of two independent experiments. As a
control, the bottom histogram shows the induction of Foxp3 that
occurs in 5C.C7 T cells in response to low doses of i.v. MCC
peptide.
Found at: doi:10.1371/journal.pbio.1000481.s009 (1.59 MB EPS)
Figure S10 No significant differences in ppErk, SHP-1,
and PTEN levels between MCC- and K5-stimulated
5C.C7 T cells. B10.A mice containing adoptively transferred
5C.C7 T cells were immunized with LPS+MCC or K5 peptide.
2.5 d after immunization, lymph node samples were fixed
immediately after harvest, methanol permeabilized, and stained
with fluorophore-conjugated antibodies to ppErk, SHP-1, or
PTEN (C). Histograms are gated on CD4
+CD45.1
+ cells (A). The
graph in (C) shows that fewer K5 stimulated 5C.C7 T cells are
present at the 2.5 d time point. The black histograms in (C) show
the levels of the ppErk, SHP-1, and PTEN in endogenous CD4
+ T
cells.
Found at: doi:10.1371/journal.pbio.1000481.s010 (0.86 MB EPS)
Figure S11 Specificity controls for phosphoantibodies.
B10.A mice containing adoptively transferred 5C.C7 T cells were
immunized with LPS alone or LPS+MCC peptide. 2.5 d after
immunization, lymph node samples were fixed immediately after
TCR Ligand Potency and In Vivo T cell Responses
PLoS Biology | www.plosbiology.org 10 September 2010 | Volume 8 | Issue 9 | e1000481harvest, methanol permeabilized, and stained with the indicated
phospho-antibodies. In the right panels, the antibodies were
incubated with a peptide corresponding to the reactive phospho-
epitope (according to the manufacturer’s protocol) prior to staining
of lymph node samples. (A) pAkt (S473). (B) pStat3 (Y705).
Found at: doi:10.1371/journal.pbio.1000481.s011 (0.92 MB EPS)
Figure S12 pAkt and pStat staining of in vitro–stimulat-
ed 5C.C7 T cells. Lymph node cells from 5C.C7 RAG22/2
mice were stimulated with irradiated CD11c+ splenic DCs and the
indicated peptide for 60 h. Cells were fixed, methanol permeabi-
lized, and stained with antibodies to pAkt (S473) (A) or pStat3
(Y705) (B). Histograms are gated on CD4+ cells and percentages of
phospho-Akt or phospho-Stat3 are shown.
Found at: doi:10.1371/journal.pbio.1000481.s012 (0.82 MB EPS)
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